Monogram Announces Conference Call
April 26 2007 - 6:10PM
PR Newswire (US)
Leading HIV Physician, Dr. Andrew Zolopa, to Discuss the
Opportunity for Monogram's Trofile(TM) Assay SOUTH SAN FRANCISCO,
Calif., April 26 /PRNewswire-FirstCall/ -- Monogram Biosciences,
Inc., (NASDAQ:MGRM) announced that it will hold a conference call
on Wednesday, May 2, 2007 at 4:30 p.m. (Eastern Time) to review the
opportunity for its Trofile(TM) Assay in the light of the FDA
Advisory Panel's recommendation that Pfizer's maraviroc be
approved. Dr. Andrew Zolopa, Assistant Professor of Medicine at
Stanford University, and a leading HIV specialist, will provide his
analysis of how Monogram's Trofile Assay may be used in clinical
practice with maraviroc. Monogram will also review its first
quarter 2007 financial results. The call will be hosted by Mr.
William D. Young, Chairman & CEO of Monogram. To participate in
the live teleconference, please call (800) 565-5442 or (913)
312-1298 for international callers, fifteen minutes before the
conference begins. Live audio of the call will be simultaneously
broadcast over the Internet and will be available to members of the
news media, investors and the general public. Access to live and
archived audio of the conference call will be available by
following the appropriate links at http://www.monogrambio.com/ and
clicking on the Investor Relations link. Following the live
broadcast, a replay of the call will also be available at (888)
203-1112 or (719) 457-0820 for international callers, through
Saturday, May 12, 2007. The replay passcode is 4138334 The
information provided on the teleconference is only accurate at the
time of the conference call, and Monogram will take no
responsibility for providing updated information except as required
by law. About Monogram Biosciences, Inc. Monogram is advancing
individualized medicine by discovering, developing and marketing
innovative products to guide and improve treatment of serious
infectious diseases and cancer. The Company's products are designed
to help doctors optimize treatment regimens for their patients that
lead to better outcomes and reduced costs. The Company's technology
is also being used by numerous biopharmaceutical companies to
develop new and improved antiviral therapeutics and vaccines as
well as targeted cancer therapeutics. More information about the
Company and its technology can be found on its web site at
http://www.monogrambio.com/. contacts: Alfred G. Merriweather
Jeremiah Hall Chief Financial Officer Feinstein Kean Healthcare
Tel: 650 624-4576 Tel: 415 677-2700 DATASOURCE: Monogram
Biosciences, Inc. CONTACT: Alfred G. Merriweather, Chief Financial
Officer of Monogram Biosciences, Inc., +1-650-624-4576, , or
Jeremiah Hall, Feinstein Kean Healthcare, +1-415-677-2700, Web
site: http://www.monogrambio.com/
Copyright
Monogram Technologies (NASDAQ:MGRM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Monogram Technologies (NASDAQ:MGRM)
Historical Stock Chart
From Jul 2023 to Jul 2024